Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 3/2004

01-06-2004 | ORIGINAL ARTICLE

Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil

Authors: Heitetsu Sai, Michihide Mitsumori, Chikako Yamauchi, Norio Araki, Setsuko Okumura, Yasushi Nagata, Yasumasa Nishimura, Masahiro Hiraoka

Published in: International Journal of Clinical Oncology | Issue 3/2004

Login to get access
Metadata
Title
Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil
Authors
Heitetsu Sai
Michihide Mitsumori
Chikako Yamauchi
Norio Araki
Setsuko Okumura
Yasushi Nagata
Yasumasa Nishimura
Masahiro Hiraoka
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 3/2004
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-004-0385-5

Other articles of this Issue 3/2004

International Journal of Clinical Oncology 3/2004 Go to the issue

ORIGINAL ARTICLE

Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck

CASE REPORT

Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer

CASE REPORT

Cardiac metastasis from Merkel cell skin carcinoma

LETTER TO THE EDITOR

A young woman with clear cell adenocarcinoma of the uterine cervix

CASE REPORT

Cutaneous and subcutaneous metastases of rectal cancer

CASE REPORT

Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits